| (Any HCV testing vs. No testing) |
---|---|
OR (95% CI) | |
Predictor variables | Â |
 Director race/ethnicity |  |
  African-American | 1.98 (0.65, 5.96) |
  Other race/ethnicity | 0.42 (0.13, 1.27) |
  White | 1†|
 Director age | 1.01 (0.97, 1.03) |
 Director gender |  |
  Female | 0.67 (0.37 1.18) |
  Male | 1†|
 Director education |  |
  Post-graduate training or more | 0.57 (0.28, 1.16) |
  College or less | 1†|
 Director sources of information | 1.50 (0.87, 2.58) |
 Director support of preventive services | 1.39 (1.02, 1.90)* |
Control variables | Â |
  Patient characteristics |  |
  Percent African-American patients | 0.99 (0.97, 1.00)^ |
  Percent Hispanic / Latino patients | 1.03 (1.00, 1.04)* |
  Percent female patients | 0.99 (0.96, 1.00) |
  Percent persons who inject drugs | 1.00 (0.99, 1.01) |
  Program characteristics |  |
  CARF accreditation |  |
   Yes | 1.53 (0.75, 3.10) |
   No | 1†|
  Ownership |  |
   Public | 1.10 (0.43, 2.76) |
   Private for-profit | 1.12 (0.53, 2.34) |
   Private not-for-profit | 1†|
  Method of treatment |  |
   Both (Meth + Bup) | 6.41 (1.69, 24.1)* |
   Buprenorphine only (Bup) | 1.32 (0.58, 2.99) |
   Methadone only (Meth) | 1†|
  Staff - patient ratio | 1.34 (0.91, 1.94) |
  Prior authorization | 1.00 (0.98, 1.00) |
  Revenue from federal sources |  |
   At least 1% | 1.40 (0.71, 2.73) |
   None | 1†|
  Revenue from private insurance |  |
   At least 1% | 0.67 (0.33, 1.33) |
   None | 1†|
  Year |  |
   2005 | 0.30 (0.15, 0.58)*** |
   2011 | 1†|